The chief executive of Medicines Australia discusses the health technology assessment review, where she is now a member of its reference committee, the associat...

Rare Cancers Australia founder and CEO sits down for a discussion with BioPharmaDispatch and challenges the early directions of the health technology review whi...

BPD Conference - Election predictions

BPD Conference 2022 Nicole Cooper

'Sights and sounds' of BPD Conference 2022

Dexcom's Scott Moss

Scott Moss, the vice president and general manager of Dexcom Asia Pacific, discusses recent and future developments in the management and treatment of insulin-d...

Pfizer's Anne Harris on 'authentically' working towards reconciliation

Better Access Australia

Bayer's Ashraf Al-Ouf on the need for objectives and KPIs

Biljana Naumovic on need for 'political will' to drive change

Dr Sarah White. QUIT

Kathryn Evans full

Nicole Cooper: The idea of 'inviting in the patient voice' is

Australia and UK counterparts on method, policy and process reviews

Professor David Thomas

Professor David Thomas spoke with BioPharmaDispatch about 'precision medicine', what it means for cancer treatment and the need for change so that patients 

GBMA Chair on the association's new agreement

GBMA Chair on the association's new agreement

MA Chair: 'This has taken a village, and I think change does take a village'

MA's Liz de Somer welcomes new agreement with the government

Better Access Australia chair and co-founder Felicity McNeill PSM

Better Access Australia chair and co-founder Felicity McNeill PSM says the system-level problems afflicting health decision-making require system-level solution...

AbbVie's Chris Stemple on being a Best Place to Work

AbbVie's Chris Stemple on being a Best Place to Work

Founder and CEO of Spinal Muscular Atrophy Australia Julie Cini

The founder and CEO of Spinal Muscular Atrophy Australia Julie Cini says the federal government needs to take control of state and territory newborn screening p...

AbbVie's Chris Stemple on biosimilars, the cost of delays and doing better on pa

In an extended interview, AbbVie's Chris Stemple discusses the recent success of biosimilars, the challenge and cost of delays in reimbursing new medicines and ...

AbbVie's Chris Stemple on biosimilars, the cost of delays and doing better on pa

In an extended interview, AbbVie's Chris Stemple discusses the recent success of biosimilars, the challenge and cost of delays in reimbursing new medicines and ...

Lisa Golden on biosimilar uptake

Lisa Golden, the group general manager of marketing for Arrotex Pharmaceuticals, spoke with BioPharmaDispatch about the company's move into biosimilar, their in...

Health minister Greg Hunt - BPD 2021

HealthDispatch Rachel David IV part 1 cut 1 190421

The Pharmacy Guild's Trent Twomey

BMS' Greg Cook on enhancing regulatory and reimbursement processes

Greg Cook, the director of access policy and advocacy for Bristol Myers Squibb Australia and New Zealand, spoke with BioPharmaDispatch about the company's subm...

MA's Liz de Somer on a busy year and the vision for industry

The Medicines Australia chief executive spoke with BioPharmaDispatch about 2020 and the long-term vision for the industry.

The 'opportunity' with the harmonisation of standards for clinical trial sites

James McAdam, the head of Government Affairs and Policy at Bristol Myers Squibb, spoke to BioPharmaDispatch about the opportunity for Australia to build its ex...

BPD James McAdam BMS Teaser cut 4 141220

Martin Palin: The rules of reputation remain unchanged

The basics underpinning a good reputation will not change in a past-pandemic world, says the managing director of Palin Communications, Martin Palin.

Pfizer's Anne Harris

Barbara Weisel on trade policy and the US election

MA's Liz de Somer on the gains in Budget 2020-21

Medicines Australia CEO Liz de Somer spoke with BioPharmaDispatch about Budget 2020-21, the medicines guarantee, cost-offsets and the negotiation of a new agree...

BIO's Joe Damond on US pricing and the 'executive order'

Joe Damond, the executive vice president of international affairs at US-based BIO, told BioPharmaDispatch the Trump administration's move on pricing is based on...

MSD's Michael Azrak on building a better system

MSD managing director and Medicines Australia board member Michael Azrak talks about the fifth anniversary of Keytruda on the PBS and building a better system.

BPD Richard Tew Novartis IV cut 1 310820

Medicines NZ - Graeme Jarvis

Medicines NZ CEO Graeme Jarvis on the new election date, the hope of wider consultation on PHARMAC's principal supply proposal and how the industry and patients...

AbbVie's Chris Stemple on being a 'best place to work'

Roche general manager Stuart Knight on 'transformation'

BioPharmaDispatch spoke with Roche general manager and Medicines Australia board member Stuart Knight about the company's recently announced 'transformation'.

MA's Liz de Somer on potential treatments, vaccines and clinical trials

MA's Liz de Somer on managing supply

AstraZeneca manufacturing and tree-planting announcement

Merck Australia Macquarie Park office

AZ's Pascal Soriot: 'My Australia and the new AstraZeneca'

Pfizer moves to 'agile' working

Pfizer's New CBD Office

Carlo Montagner on the global vision for Specialised Therapeutics

Insights from MSD's Michael Azrak

Pfizer's Melissa McGregor: 'How we're working today and tomorrow'

Dr Freda Lewis-Hall on 'humanising' the industry

NPSA: The future of the CSO

PharmaDispatch conference - Budget 2018-19

PharmaDispatch conference - Predictability and certainty

PharmaDispatch Conference - National Medicines Policy

PharmaDispatch 2018 conference video

PharmaDispatch 2018 conference

Pam Cheng, executive vice president, global operations and IT, AstraZeneca

If Australia wants investment in new manufacturing it has to make the case, says AstraZeneca's global head of operations and IT.

Liz Chatwin, country president, AstraZeneca Australia and NZ